2-(1-isopropyl-piperidin-4-yloxy)-4,7-dihydro-5H-thieno[2,3-c]pyridine-6-carboxylic acid diethylamide | 1032707-10-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 2-(1-isopropyl-piperidin-4-yloxy)-4,7-dihydro-5H-thieno[2,3-c]pyridine-6-carboxylic acid diethylamide
• 英文别名: N,N-diethyl-2-(1-propan-2-ylpiperidin-4-yl)oxy-5,7-dihydro-4H-thieno[2,3-c]pyridine-6-carboxamide
• CAS: 1032707-10-0
• 化学式: C₂₀H₃₃N₃O₂S
• 分子量: 379.567
• InChiKey: YDLWBZGXWDHTKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  64.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C<br/>[FR] DÉRIVÉ D'URACILE OU DE THYMINE POUR LE TRAITEMENT DE L'HÉPATITE C
  申请人：ABBOTT LAB

  公开号：WO2009039127A1

  公开（公告）日：2009-03-26

  Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.

  本申请涉及一种用于治疗丙型肝炎（HCV）感染的化合物，其化学式为I。所述化合物的结构中，尿嘧啶或胸腺嘧啶衍生物通过苯基与融合的2环环系统（R6）或者通过额外的两原子连接物（L）与5-6环单环（R6）相连。该申请还揭示了两种特定化合物的多晶形和伪多晶形：N-(6(3-叔丁基-5-(2>4-二氧化-3,4-二氢嘧啶-1(2H)-基)2-甲氧基苯基)萘-2-基)甲磺酰胺和(E)-N-(4(3-叔丁基-5-(2,4-二氧化-3,4-二氢嘧啶-1(2H)-基)2-甲氧基-苯乙烯基苯基)甲磺酰胺。
• 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
  申请人：Chen Li

  公开号：US20080146559A1

  公开（公告）日：2008-06-19

  The present invention relates to compounds of formula I wherein R 1 and R 2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及式I的化合物，其中R1和R2如描述和权利要求中定义，并且其药用盐。这些化合物可用于治疗和/或预防与H3受体调节相关的疾病。
• 4,5,6,7-TETRAHYDRO-THIENO [2,3-C]PYRIDINES AS H3 MODULATORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2102215B1

  公开（公告）日：2010-09-01
• URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C
  申请人：Abbott Laboratories

  公开号：EP2222646A1

  公开（公告）日：2010-09-01